AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Leider ja

Entschuldigung: 4 $

Aufgrund positiver Entwicklungen und größerer Stabilität (nur noch 5 % Shortquote) bin ich vorübergehend zu Jazz Pharmaceuticals gewechselt.

Short quote von 21 % auf etwa 19 %. Also wird abgebaut.

AbCellera announces collaboration with Vertex Pharmaceuticals TheFly Jul 29, 2026, 01:27 PM AbCellera (ABCL) announced a collaboration with Vertex Pharmaceuticals Incorporated (VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers, TCEs, for autoimmune diseases and other conditions. Under the terms of the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery and early development activities. Vertex will fund all research and development costs and will have the right to develop and commercialize therapeutic multispecific antibodies resulting from the collaboration. AbCellera will receive $28M in total upfront payments and is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales. In addition, AbCellera and Vertex may mutually agree to have AbCellera perform cell line development, process development, and clinical manufacturing through Phase 1 for any program under the collaboration.

Alta was hier wieder für eine kacke

Chippers gewinnen wieder.

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT) Catie Powers Jul 17, 2026, 12:30 PM AbCellera Biologics (ABCL) In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on AbCellera Biologics, with a price target of $11.00. The company’s shares closed last Thursday at $6.16. According to TipRanks.com, Seedhouse is a 5-star analyst with an average return of 11.4% and a 45.9% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Belite Bio, Inc. ADR, Viking Therapeutics, and Aligos Therapeutics. Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $10.20, a 53.4% upside from current levels. In a report issued on July 15, JonesTrading also maintained a Buy rating on the stock with a $13.00 price target.

Ich denke es lohnt sich nachzukaufen. Aber bei dieser Aktie muss man echt sehr aufmerksam sein, um richtig ein- und auszusteigen.

Ein weiterer typischer Kurssturz, ausgelöst durch Leerverkäufer (20 %). Das setzt sich den ganzen Tag über fort. Ich kaufe immer zu früh und werde dabei erwischt. Aber ich glaube, das sind die letzten Zuckungen. Die Lage bessert sich.

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL) Brian Anderson Jul 15, 2026, 08:20 PM AbCellera Biologics (ABCL) JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on AbCellera Biologics today and set a price target of $13.00. The company’s shares closed last Wednesday at $6.74. According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of 50.5% and a 69.0% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and EyePoint Pharmaceuticals. Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $9.40.

Gemini: The upfront payment from Jazz Pharmaceuticals to AbCellera took place when the companies officially signed and announced their collaboration agreement on June 17, 2026.Breakdown of the Upfront PaymentsInitial Upfront Amount: Jazz issued a $56 million upfront payment to cover the initiation of the first two preclinical research programs.Subsequent Upfront Amount: An additional $28 million payment is structured to take place within the next 12 months, immediately upon the initiation of a committed third discovery program.The full agreement, which focuses on developing next-generation T-cell engaging antibodies for solid tumors, could eventually reach over $2.4 billion if Jazz exercises all future development and commercial milestone options.

ABCL Upgraded by Benchmark -- Price Target Announced at $11.00 GuruFocus News 07/07/2026 14:43 On October 03, 2023, AbCellera Biologics received an upgrade from Benchmark, as analyst Robert Wasserman changed the rating from Hold to Buy. The price target has been announced at $11.00, marking a significant shift in the analyst's outlook on the stock. What's Behind the Analyst Rating? The recent upgrade from Benchmark reflects a more optimistic view on AbCellera Biologics' potential to deliver value to shareholders. The new price target of $11.00 suggests that the analyst believes the stock has considerable upside potential from its current trading price of $7.87. This change in rating comes amid a backdrop of evolving market conditions and the company's ongoing developments in the biotechnology sector.

Die AbCellera-Aktie steht nach ihrer kräftigen Korrektur erneut im Fokus der Anleger. Nach dem deutlichen Rücksetzer stellt sich nun die Frage, ob sich auf dem aktuellen Kursniveau eine attraktive Einstiegsgelegenheit bietet oder ob die Abwärtsbewegung noch nicht abgeschlossen ist. Entscheidend wird sein, ob sich die Aktie an wichtigen Unterstützungen stabilisieren und den Grundstein für eine nachhaltige Trendwende legen kann. Wie es für den Kurs der Aktie weitergehen könnte, zeigt die folgende Chartanalyse. https://www.finanznachrichten.de/nachrichten-2026-07/69006062-abcellera-aktie-chance-nach-der-korrektur-486.htm

😮‍💨